# Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

> **NCT03318939** · PHASE2 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 648 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Poziotinib

## Key facts

- **NCT ID:** NCT03318939
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-13
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-04-03
- **Target enrollment:** 648 (ACTUAL)
- **Why stopped:** Strategic business decision (unrelated to safety)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03318939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03318939, "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03318939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*